Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka Bags Rights to Bispecific T-Cell Engager from China’s Harbour
June 24, 2025
- Ono Snags Japan, Korea Rights to Vertex’s Povetacicept
June 24, 2025
- GMP Deviation at CMO Katsuyama Caused Viatris Shipment Halt
June 23, 2025
- Boehringer to Invest 300 Million Euros in New Facilities at Yamagata Plant
June 23, 2025
- GSK’s RSV Vaccine Arexvy Filed for High-Risk Adults Aged 18-49 in Japan
June 23, 2025
- Moderna Files Next-Gen COVID Vaccine in Japan
June 23, 2025
- SanBio, Minaris Aim to Expand Global Reach of Akuugo
June 20, 2025
- Japan Rare Disease Drug Market to Grow Nearly 70% by 2040: Fuji Keizai
June 20, 2025
- Viatris Pauses Shipments of Polyful, Other Drugs over Manufacturing Issues
June 20, 2025
- Vietnam Clears Epadel for Import, Launch Planned via Partner: Mochida/Meiji
June 20, 2025
- Shionogi Clinches Tender Offer for Torii, Sets Stage for Full Takeover by September
June 20, 2025
- NEC Reports Positive Results in AI Demo for Predicting Cancer Drug Combos
June 19, 2025
- Axcelead, Lotte, Kanaph Join Forces to Push ADCs
June 19, 2025
- Will Moderna See Multiple Japan Filings in the Coming Years? 5 Late-Stage Assets in Pipeline
June 19, 2025
- Taking on Solid Tumors - 6: Pfizer Japan Sees Rosy Uptake with Elrexfio, Mulling Bringing Bispecific Assets for Solid Cancers Too
June 18, 2025
- Otsuka’s Therapeutic App for Depression Now Available in Great Britain
June 18, 2025
- Alfresa Teams Up with HekaBio, Swanielle to Fight Drug Lag/Loss
June 18, 2025
- Axcelead, A2 Healthcare Pair Up to Eliminate Drug Loss
June 18, 2025
- Chugai Halts Dosing of Non-Ambulatory Patients in DMD Gene Therapy Trial after 2 Deaths Overseas
June 17, 2025
- Astellas, MRI Join Hands to Support Startups via MEDISO
June 17, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…